A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

Keyphrases

• Phase II Study 100%
• Metastatic Breast Carcinoma 100%
• Mesylate 100%
• Exatecan 100%
• Pharmacokinetic Profile 50%
• Anthracyclines 50%
• Taxanes 50%
• Disease Progression 33%
• Stable Disease 33%
• Prior Chemotherapy 33%
• Linear Pharmacokinetics 33%
• Pharmacokinetics 16%
• Headache 16%
• Chemotherapy 16%
• Antitumor Activity 16%
• Median Survival 16%
• Blood Samples 16%
• Clinical Evidence 16%
• Disease Resistance 16%
• Am(III) 16%
• Nausea 16%
• Constipation 16%
• Safety Profile 16%
• Activity Profile 16%
• Toxicity Profile 16%
• Neutropenia 16%
• Emesis 16%
• Partial Response 16%
• Elimination Half-life 16%
• Volume of Distribution 16%
• Plasma Clearance 16%
• Median Time 16%
• Nonhematologic 16%
• Myalgia 16%
• Dose Administration 16%
• Paresthesia 16%
• Multiple Dose 16%
• Camptothecin Derivatives 16%
• Starting Dose 16%
• Measurable Disease 16%
• Severe Adverse Events 16%
• Moderate Activity 16%
• Chemotherapy Exposure 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Carcinoma 100%
• Exatecan 100%
• Pharmacokinetics 66%
• Disease 50%
• Anthracycline 50%
• Taxane 50%
• Disease Exacerbation 33%
• Patient History of Chemotherapy 33%
• Antitumor Activity 16%
• Chemotherapy 16%
• Elimination 16%
• Headache 16%
• Adverse Event 16%
• Nausea 16%
• Vomiting 16%
• Constipation 16%
• Myalgia 16%
• Disease Resistance 16%
• Camptothecin Derivative 16%
• Paresthesia 16%
• Neutropenia 16%
• Volume of Distribution 16%